Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, March 2014

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

blogs: 2 blogs
twitter: 4 X users

wikipedia: 10 Wikipedia pages

Citations

dimensions_citation: 122 Dimensions

Readers on

mendeley: 157 Mendeley

Summary Blogs X Wikipedia Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 13,970 followers.

RT @BlancFrdric7: Le Lecanemab appelé aussi BAN2401 agirait sur les protofibrilles amyloides. https://t.co/N98Rk8qMpU

08 Dec 2022

Reply Repost Favourite

Les protofibrilles seraient particulièrement toxiques notamment sur la synapse. https://t.co/9JGJf0Z5ys

08 Dec 2022

Reply Repost Favourite

Le Lecanemab appelé aussi BAN2401 agirait sur les protofibrilles amyloides. https://t.co/N98Rk8qMpU

08 Dec 2022

Reply Repost Favourite

has at least a 1,000-fold higher selectivity for protofibrils as compared with monomers of Aβ, thus targeting the toxic species of the peptide. A humanized version of mAb158, BAN2401, has now entered a clinical https://t.co/f7plNcdyOk

25 Jul 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.